- Home
- ZVRA vs PROK Comparison
ZVRA vs PROK Comparison
Compare ZVRA & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVRA
- PROK
- Stock Information
- Founded
- ZVRA 2006
- PROK 2015
- Country
- ZVRA United States
- PROK United States
- Employees
- ZVRA N/A
- PROK N/A
- Industry
- ZVRA Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZVRA Health Care
- PROK Health Care
- Exchange
- ZVRA Nasdaq
- PROK Nasdaq
- Market Cap
- ZVRA 467.6M
- PROK 417.1M
- IPO Year
- ZVRA 2015
- PROK N/A
- Fundamental
- Price
- ZVRA $8.99
- PROK $2.43
- Analyst Decision
- ZVRA Strong Buy
- PROK Strong Buy
- Analyst Count
- ZVRA 7
- PROK 4
- Target Price
- ZVRA $21.71
- PROK $6.25
- AVG Volume (30 Days)
- ZVRA 1.5M
- PROK 1.6M
- Earning Date
- ZVRA 11-05-2025
- PROK 11-10-2025
- Dividend Yield
- ZVRA N/A
- PROK N/A
- EPS Growth
- ZVRA N/A
- PROK N/A
- EPS
- ZVRA 0.54
- PROK N/A
- Revenue
- ZVRA $84,388,000.00
- PROK $744,000.00
- Revenue This Year
- ZVRA $336.43
- PROK $471.74
- Revenue Next Year
- ZVRA $54.26
- PROK N/A
- P/E Ratio
- ZVRA $16.52
- PROK N/A
- Revenue Growth
- ZVRA 244.60
- PROK N/A
- 52 Week Low
- ZVRA $6.19
- PROK $0.46
- 52 Week High
- ZVRA $13.16
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- ZVRA 38.60
- PROK 37.96
- Support Level
- ZVRA $8.51
- PROK $2.56
- Resistance Level
- ZVRA $9.69
- PROK $2.88
- Average True Range (ATR)
- ZVRA 0.58
- PROK 0.25
- MACD
- ZVRA -0.15
- PROK -0.08
- Stochastic Oscillator
- ZVRA 15.26
- PROK 19.34
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.